Skip Navigation


European Heart Journal Advance Access originally published online on March 31, 2005
European Heart Journal 2005 26(10):953-955; doi:10.1093/eurheartj/ehi233
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/10/953    most recent
ehi233v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Deng, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deng, M. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

The challenges of generating evidence to guide mechanical circulatory support-based management of advanced heart failure

Mario C. Deng*

Department of Medicine, Columbia University College of Physicians & Surgeons, New York, NY 10032, USA

* Corresponding author. Tel: +1 212 305 0200; fax: +1 212 305 7439. E-mail address: md785@columbia.edu

The first 10% of the full text of this article appears below.

This editorial refers to ‘Advanced heart failure: feasibility study of long-term continuous axial flow pump support’{dagger} by M.P. Siegenthaler et al., on page 1031

The heart failure epidemic is increasing globally. The epidemiological transition will, because of (i) a reduction of mortality from infectious diseases and (ii) increased life expectancy, go with an increased mortality risk secondary to cardiovascular diseases including heart failure. Within this background scenario, in the USA and Europe alone, with more than 600 million inhabitants and more than 6 million patients with heart failure, the prevalence of advanced heart failure, constituting 1–10% of the heart failure population, is estimated to total between 60 000 and 600 000 patients.

Correspondingly, the evolution of treatment options for advanced heart failure patients over the last decades has been impressive. It includes medical treatment (angiotensin-converting enzyme inhibitors, beta-blockade), defibrillator therapy, heart transplantation, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Advanced heart failure: feasibility study of long-term continuous axial flow pump support
Michael P. Siegenthaler, Stephen Westaby, O.H. Frazier, Jürgen Martin, Adrian Banning, Desiree Robson, John Pepper, Phillip Poole-Wilson, and Friedhelm Beyersdorf
EHJ 2005 26: 1031-1038. [Abstract] [FREE Full Text]